Pep-Talk
Cjc-1295 vial

Cjc-1295

Educational resource. Not medical advice. No dosing or instructions.

Safety grade
7/10
High
Also known as
cjcCJC-1295 (no DAC)CJC-1295 DACGHRH analogcjc 1295cjc 1295 no daccjc no daccjc-1295cjc-1295 no daccjc1295cjc1295 no daccjc1295 nodac
AA sequence
Not available yet.
What it is
CJC-1295 is a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling. Controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain.
Refs: E1

Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.

Why people are interested
  • a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling
  • controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain
  • general recovery and resilience interest (anecdotal)
  • common biohacker curiosity due to community reports
  • interest in mechanisms suggested by early evidence
  • used in goal-based stacking discussions (anecdotal)
  • exploration in wellness communities despite evidence limits
Use cases (real-world)
These are the most common real-world reasons people look into this peptide, plus the context that tends to matter most (quality, expectations, and safety).
sleep and recovery interest tied to GH physiology (real-world reports vary)
body composition interest in training communities (outcomes vary)
sometimes discussed alongside other GH-axis peptides (stacking culture)

CJC-1295 is a GHRH analog discussed to stimulate growth-hormone signaling. It can meaningfully affect endocrine physiology, appetite, fluid balance, and glucose control.

Common reasons people consider it

  • sleep and recovery interest tied to GH physiology (real-world reports vary)
  • body composition interest in training communities (outcomes vary)
  • sometimes discussed alongside other GH-axis peptides (stacking culture)

Most commonly reported downsides

  • flushing or warmth
  • water retention or swelling
  • headache

Rare but important symptoms to watch for

These are uncommon, but if they occur, stop and seek medical care.

  • worsening glucose control in susceptible users
  • severe swelling, palpitations, or fainting

Who should be cautious

  • people with diabetes, prediabetes, or metabolic syndrome
  • people with active cancer or a high cancer-risk history (growth signaling context)
  • pregnant or breastfeeding individuals
  • adolescents (endocrine-axis impact plus long-term uncertainty)

Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.

Interaction summary
Interactions here are category flags — they’re meant to help you ask better questions and avoid obvious conflicts. They are not a dosing guide.
Drug-class flags to review:
endocrine-axis-modulation-context
If you’re on cardiovascular, anticoagulant/antiplatelet, serotonergic, or immunomodulating meds/supplements, treat uncertainty as a reason to slow down and verify with a clinician.
Medication classes
Endocrine Axis Modulation Context
Supplement classes
None
Other peptides
None
Developmental / Adolescent risk
Because CJC-1295 targets GH/IGF signaling, adolescents and still-developing endocrine systems should treat uncertainty as a meaningful risk. Long-term setpoint changes are not well characterized.
Refs: E1
PUBMED · Grade: human_interventional · Year: 2006
CJC-1295 increases growth hormone and IGF-1 in healthy adults (human interventional study)
Interventional human research reporting GH/IGF-1 changes. Does not establish long-term enhancement outcomes or safety in non-medical use contexts.
CJC-1295 is not an approved therapeutic drug. Human evidence exists for GH/IGF changes in controlled settings, but long-term safety and outcome evidence for enhancement use is limited. Investigational peptide discussed as a GHRH analog affecting GH/IGF signaling. Not an FDA-approved therapeutic drug.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.

Community notes

Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note